Navigation Links
Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
Date:2/8/2013

FRIDAY, Feb. 8 (HealthDay News) -- The cancer drug Avastin may extend the lives of patients with aggressive cervical cancer, a new study finds.

The findings might change the way these patients are treated and improve outcomes for women "who have previously had very limited treatment options," study lead researcher Dr. Krishnansu Tewari, said in a news release from the U.S. National Cancer Institute (NCI).

The research was sponsored by the NCI and received support from Genentech Inc., which makes Avastin.

The study included 452 women with recurrent, advanced or persistent cervical cancer that was not curable with standard chemotherapy. Patients who received Avastin with their chemotherapy lived an average of 17 months, compared with just over 13 months for those treated with chemotherapy alone, the investigators found.

The patients who received Avastin were given a dose of 15 milligrams per kilogram of body weight, which was administered in the vein with their chemotherapy treatment. The dose was given one day every three weeks until the patient's cancer progressed or levels of the drug in the body became too high.

Patients who received Avastin did have more side effects than those who didn't take the drug, the researchers noted, and the side effects were consistent with those known to be associated with Avastin -- events such as bleeding, clotting and gastrointestinal issues.

Avastin also comes with a hefty price tag, about $5,000 per month.

Still, the increase in survival seen with Avastin "is welcome news as progress has been very difficult against this cancer," Dr. Jeff Abrams, clinical director of NCI's Division of Cancer Treatment and Diagnosis, said in the news release.

Another expert not connected to the study agreed.

Dr. Elizabeth Poynor, a gynecologic oncologist and pelvic surgeon at Lenox Hill Hospital in New York City, noted that women with advanced cervical cancers that pro
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. FDA Issues Another Warning on Fake Version of Cancer Drug Avastin
2. Avastin Shows No Benefit for Earlier Colon Cancer: Study
3. Avastin Wont Extend Breast Cancer Survival: Study
4. Interpreting the Avastin-Lucentis study for persons with macular degeneration
5. Avastin No Benefit to Older Lung Cancer Patients: Study
6. More Fake Avastin Found in U.S., FDA Says
7. A Good Mood May Boost Seniors Brain Power
8. Living Near Equator May Boost Your Risk for Allergy, Asthma
9. Personalized plans to address barriers to HIV drug adherence boost chances of successful therapy
10. Fried Foods May Boost Prostate Cancer Risk, Study Says
11. Plastic Surgery Practice Gets Boost from Lower Eyelid Surgery Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... For Dallas, ... is taking part with their subsidiary USPI Tenet Health. , The American Heart Association ... heart disease and stroke. They believe that together, a difference can be made. Walkers ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... ... Saint Petersburg, FL —Pocket Protein™, a protein beverage that ... lactose or caffeine in a convenient 2 oz. pouch that never needs refrigeration, ... , Five consumer packaged goods (CPG) products were selected by the SupplySide editorial ...
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... 28, 2015 , ... CARF International announced that West Ridge ... treatment and intensive family based services. , By pursuing and achieving accreditation, West ... of excellence. As a nonprofit charity for more than 50 years, West Ridge ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Cellular damage induced by oxygen free radicals may be ... new study. //This groundbreaking study conducted by neuroscientists at ... of complex I, a protein that plays a major ... has been blamed for cellular damage in Parkinson’s disease. ...
... yet ascertained the top floors of the Melbourne office block ... the cause of illnesses.// ,Tests on radiofrequency emissions, ... any link as yet to the seven cases of brain ... of these seven cases were employees who had worked on ...
... genetic disorder which completely affects the immune system. In ... //therapy was successfully used to cure this life threatening ... Of Veterinary Medicine and the National Institute of Allergy ... as a vector for the correct gene of XSCID. ...
... of several previous studies of TNF- (tumor necrosis factor) ... that use of these drugs causes an increased risk ... study shows a strong association between treatment with TNF-blocking ... pneumonia, and cancers,' says Eric Matteson, M.D., Mayo Clinic ...
... a pigment that imparts tomatoes its characteristic red color ... ideal for prevention of strokes and heart attacks.// Previous ... chemical. ,According to scientists, the stickiness of ... - was reduced by 70 percent when 220 volunteers ...
... issue of Cancer Cell says that scientists have identified ... how cancer progresses.// This molecule was found to inhibit ... vivo as well as in vitro. , ,This ... inhibitors must display a broad reactivity to effectively attenuate ...
Cached Medicine News:Health News:Oxygen-Induced Damage A Leading Cause For Parkinson’s Diseas 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 3Health News:Risk of Cancer from Drugs for Rheumatoid Arthritis 2Health News:Risk of Cancer from Drugs for Rheumatoid Arthritis 3Health News:Discovery Of New Molecule Could Solve Cancer Spread Mystery 2
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ... Report on China,s Bevacizumab Market ,2010-2019" report to ... trade name of Avastin, bevacizumab injection is the first ... was approved by CFDA to treat metastatic colorectal cancer. ... all come from Roche and its subsidiary Genectech. ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Quetiapine ... Developed by AstraZeneca plc, quetiapine (under the ... for the treatment of schizophrenia. Approved by CFDA ... in the Catalogue of Drugs for the Basic ...
(Date:8/28/2015)... Aug. 28, 2015  IP Shakti, LLC, today announced that ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... "Our new corporate identity signifies our transformation into a company ... analytics platform for patent claim validity." ... the proprietary AIA Shield™ platform, the Company commenced a corporate ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... Tenn., Aug. 30 ,Palatin Technologies, Inc. (Amex: ... ) announced today that they have delayed plans ... bremelanotide, a first in class,melanocortin agonist drug candidate, ... decision follows responses from representatives of,the U.S. Food ...
... FRANCISCO, Calif., Aug. 29 ,Exelixis, Inc. (Nasdaq: EXEL ... for analysts and investors in conjunction with the International,Association ... Conference on,Lung Cancer. The webcast will be held on ... During the webcast, Exelixis management will,discuss data from a ...
Cached Medicine Technology:King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction 2Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing 2
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... is a 1-step, hand-held, point-of-care device for the ... human urine. The TOX/See device can detect ... drugs in 3 to 8 minutes and requires ... cassette is individually packaged to maximize convenience and ...
Medicine Products: